Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC) J Surg Oncol 98: 485-489

Author(s): Duffy A, Capanu M, Abou-Alfa GK, Huitzil D, Jarnagin W, et al.

Abstract

Background

The incidence of gallbladder cancer (GBC) in the US is 1.2/100,000. This report examines the patterns of presentation, adjuvant treatment and survival of a large cohort of patients with GBC evaluated at MSKCC over a 10-year period.

Methods

A retrospective analysis of patients referred to MSKCC with a diagnosis of GBC between January 1995 and December 2005 was performed. Patients were identified from the MSKCC cancer registry. Information extracted included, demographics, clinical and pathological stage, surgical management, pathology, adjuvant and palliative therapy, date of relapse, death or last follow-up. Date of diagnosis was defined as date of surgery or biopsy. Survival curves were estimated using the Kaplan–Meier method and compared using the log-rank test.

Similar Articles

Neuroendocrine tumours of the gallbladder: three cases and a review of the literature

Author(s): Iype S, Mirza TA, Propper DJ, Bhattacharya S, Feakins RM, et al.

Two cases of small cell carcinoma of the gallbladder

Author(s): Nau P, Liu J, Dillhoff M, Forster M, Hazey J, et al.

Combined neuroendocrine cell carcinoma and adenocarcinoma of the gallbladder: A report of a case

Author(s): Shimizu T, Tajiri T, Akimaru K, Arima Y, Yoshida H, et al.

Neuroendocrine tumor epidemiology: contrasting Norway and North America

Author(s): Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system

Author(s): Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, et al.

NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors

Author(s): Clark OH, Benson AR, Berlin JD, Choti MA, Doherty GM, et al.

Gastroenteropancreatic neuroendocrine tumours

Author(s): Modlin IM, Oberg K, Chung DC, Jensen RT, De Herder WW